\nAc\u0163iunile companiei elve\u0163iene de biotehnologie Relief Therapeutics, care creeaz\u0103 un medicament pentru afec\u0163iunile respiratorii provocate de coronavirus, au crescut cu 38.000% \u00een 2020, potrivit CNBC.<\/p>\n
\nFirma dezvolt\u0103 un medicament numit RLF-100, care a fost lansat \u00een urm\u0103 cu 20 de ani, \u00eens\u0103 care poate proteja celulele \u00eempotriva virusului SARS-CoV-2.<\/p>\n
\nPre\u015fedintele Relief Therapeutics Ram Selvaraju a declarat c\u0103 testele vor oferi un rezultat concret \u00een prima jum\u0103tate a lunii ianuarie \u015fi a pus cre\u015fterea masiv\u0103 a ac\u0163iunilor pe seama dovezilor privind eficien\u0163a pe care a prezentat-o tratamentul \u00een r\u00e2ndurile \u201epacien\u0163ilor altminteri netratabili\u201d.<\/p>\n
\n\u201e\u00cen timp ce al\u0163i oameni s-au concentrat asupra infec\u0163iilor minore \u015fi medii, noi ne-am \u00eendreptat aten\u0163ia asupra modalit\u0103\u0163ilor prin care medicamentul ar oferi beneficii bolnavilor afla\u0163i \u00een stare grav\u0103\u201d, a ad\u0103ugat Ram Selvaraju.<\/p>\n
\nRezultatele din primele etape de testare arat\u0103 c\u0103 72% dintre pacien\u0163ii cu simptome respiratorii severe au \u00eenceput s\u0103 \u00ee\u015fi revin\u0103 dup\u0103 ce au fost trata\u0163i cu RLF-100.<\/p>\n
\nRelief Therapeutics avea o capitalizare de 100 de milioane de franci elve\u0163ieni la sf\u00e2r\u015fitul lunii iulie \u015fi, dup\u0103 ce rezultatele a 21 de pacien\u0163i trata\u0163i cu RLF-100 au fost publicate pe 10 august, valoarea de pia\u0163\u0103 a companiei a ajuns la 1,6 miliarde. \u00cen prezent, valoarea este de 1,34 miliarde de franci.<\/p>\n
\n\u00cen plus, cre\u015fterea de 38.000% surprinde pre\u0163ul redus al ac\u0163iunilor de dinainte de pandemie, de vreme ce pre\u0163ul unei ac\u0163iuni atinge luni, 14 decembrie aproape 0,42 de franci. Prin contrast, o ac\u0163iune a multina\u0163ionalei Roche valoreaz\u0103 306 franci.<\/p>\n
\n <\/p>\n","protected":false},"excerpt":{"rendered":"
Ac\u0163iunile companiei elve\u0163iene de biotehnologie Relief Therapeutics, care creeaz\u0103 un medicament pentru afec\u0163iunile respiratorii provocate de coronavirus, au crescut cu 38.000% \u00een 2020, potrivit CNBC. Firma dezvolt\u0103 un medicament numit RLF-100, care a fost lansat \u00een urm\u0103 cu 20 de ani, \u00eens\u0103 care poate proteja celulele \u00eempotriva virusului SARS-CoV-2. Pre\u015fedintele Relief Therapeutics Ram Selvaraju a […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[7172,46210,323,12923],"class_list":["post-188982","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-actiuni","tag-covid","tag-medicamente","tag-tratament"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/188982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=188982"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/188982\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=188982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=188982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=188982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}